HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cefadroxil Use for Musculoskeletal Infections in an Academic Pediatric Hospital.

Abstract
Forty-nine of 52 (94.2%) children with musculoskeletal infection (MSKI) were successfully treated with cefadroxil dosed at 30 mg/kg/day over a 10-year time period. Two failures were associated with poor medication adherence. Our study suggests that treatment of MSKI with cefadroxil offers acceptable outcomes. Confirmation through clinical trials is appropriate.
AuthorsErin Weslander, Holly Thomas, Ralph Jeune, Michael Green, John V Williams
JournalJournal of the Pediatric Infectious Diseases Society (J Pediatric Infect Dis Soc) Vol. 11 Issue 12 Pg. 590-593 (Dec 28 2022) ISSN: 2048-7207 [Electronic] England
PMID36112393 (Publication Type: Journal Article)
Copyright© The Author(s) 2022. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: [email protected].
Chemical References
  • Cefadroxil
Topics
  • Child
  • Humans
  • Cefadroxil (therapeutic use)
  • Hospitals, Pediatric

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: